Skip to content

Journal · Health economics · Updated 21 November 2026

PharmacoEconomics

Read PharmacoEconomics articles on DeepDyve. No university library needed.

PharmacoEconomics has published since 1992 and covers the economic evaluation of health care, from the value of combination vaccines and rapid diagnostic tests to screening models, knee implants and pharmacogenetic testing. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of PharmacoEconomics
Journal cover

PharmacoEconomics at a glance

Full title
PharmacoEconomics
Abbreviation (NLM)
Pharmacoeconomics
Publisher
Springer Nature
Print ISSN
1170-7690
Online ISSN (eISSN)
1179-2027
First published
1992
Subjects
Drug Therapy, Pharmacology
Access model
Hybrid (65% free to read in 2026)

Ways to access PharmacoEconomics

65% of the articles PharmacoEconomics published from January 1 to November 20, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 65% of PharmacoEconomics articles published from January 1 to November 20, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication.
  3. Ask the authors. Authors can also share a free, read-only link to their published article through Springer Nature’s SharedIt, so it’s worth asking the authors directly.
  4. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  5. A library. Your university, hospital or public library may subscribe to PharmacoEconomics. Check its journal list and whether it offers remote access.
  6. DeepDyve. Read PharmacoEconomics articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Impact factor and metrics

PharmacoEconomics’ 2025 Journal Impact Factor is 4.8, and its 5-year Impact Factor is 6.1.

4.8

Journal Impact Factor (2025)

6.1

5-year Impact Factor (2025)

7 days

Median time to first decision

1.2M

Downloads (2025)

Source: journal metrics on the PharmacoEconomics homepage (Springer Nature), checked November 21, 2026. Impact Factor from Clarivate Journal Citation Reports.

Recent PharmacoEconomics research worth reading

Published January to March 2026. Summaries describe what the authors report.

  1. Open accessVaccines · Health economics

    Estimating the Value of Combination Vaccines: A Methodological Framework

    The authors propose valuing combination vaccines across four domains, namely lower costs to caregivers, health system efficiencies, the opportunity cost of schedule slots and simpler schedules, and illustrate the framework with a hypothetical vaccine added to a crowded schedule.

    Jit et al. · PharmacoEconomics, published online January 4, 2026 · DOI 10.1007/s40273-025-01575-z

  2. Open accessBloodstream infections · Diagnostics

    Evaluating the Cost Effectiveness of Rapid Diagnostic Testing for the Identification of Pathogens and Resistance Genes in Bloodstream Infections

    In a decision-tree model of US hospital patients with suspected bloodstream infection, the authors report that adding Cobas Eplex BCID panels to standard care saved US$164 per patient and averted 24 deaths per 10,000 patients, and stayed cost effective in a UK setting.

    Karichu et al. · PharmacoEconomics, published online March 11, 2026 · DOI 10.1007/s40273-026-01608-1

  3. LitStreamType 1 diabetes · Screening

    Development of a Patient-Level Multi-objective Optimisation Model for Screening Strategies for Childhood Type 1 Diabetes

    The authors build a patient-level simulation of childhood type 1 diabetes screening and use multi-objective optimisation to identify four US screening strategies that meet commonly cited cost-effectiveness thresholds, needing a maximum of 1, 2, 3 and 4 islet autoantibody tests.

    Leiria et al. · PharmacoEconomics, published online February 9, 2026 · DOI 10.1007/s40273-025-01581-1

  4. LitStreamKnee replacement · Economic modelling

    Spectrum of Models for Assessing the Cost Effectiveness of Total Knee Replacement Implants: A Comparison of Discrete-Time Cohort Markov and Continuous-Time Individual-Level Multistate Models

    Comparing four models of increasing complexity for 12 knee implants, the authors report that simpler Markov models picked the most commonly used implant as most cost effective, while spline-based and patient-history microsimulation models identified other implants instead.

    Xu et al. · PharmacoEconomics, published online January 4, 2026 · DOI 10.1007/s40273-025-01578-w

  5. LitStreamPharmacogenomics · Cost-utility

    Economic Evaluation of Pre-emptive Pharmacogenetic Panel Testing versus No Genetic Testing in a Multi-ethnic Asian Population

    Modelling healthy 40-year-old Singaporeans, the authors report that a one-time pre-emptive pharmacogenetic panel covering four drug–gene pairs saved S$37,600 and gained 9.32 quality-adjusted life years per 1000 individuals compared with no genetic testing.

    Briones et al. · PharmacoEconomics, published online March 23, 2026 · DOI 10.1007/s40273-026-01586-4

See every PharmacoEconomics article on DeepDyve

Questions about PharmacoEconomics

How can I read PharmacoEconomics articles without a subscription?

65% of PharmacoEconomics articles published from January 1 to November 20, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors post their accepted manuscript on their own website as soon as it’s accepted, and in a repository such as PubMed Central 12 months after publication. Your library may also subscribe. DeepDyve lets you read PharmacoEconomics articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for PharmacoEconomics?

PharmacoEconomics’ NLM (PubMed) abbreviation is Pharmacoeconomics.

What is the ISSN of PharmacoEconomics?

The print ISSN is 1170-7690 and the online ISSN is 1179-2027.

What is the impact factor of PharmacoEconomics?

PharmacoEconomics’ Journal Impact Factor is 4.8 (2025), and its 5-year Impact Factor is 6.1, according to Springer Nature’s published metrics.

Is PharmacoEconomics open access?

PharmacoEconomics is a hybrid journal: authors can choose to publish open access or under the subscription model. From January 1 to November 20, 2026, 68 of 105 PharmacoEconomics articles (65%) carry a Creative Commons license, per Crossref.

PharmacoEconomics articles on DeepDyve are licensed from Springer Nature. Journal facts as of 21 November 2026.

Start reading PharmacoEconomics today

One month free, then less than $2 a day. PharmacoEconomics, plus millions of articles from thousands of journals.

Start free month

Like this: